***** $NVLX *****
When Nuvilex, Inc. (OTCQB: NVLX) announced that it had contracted Inno Biologics to generate cell clones that will be the basis of the company's future Phase III clinical trials in advanced, inoperable, pancreatic cancer, many investors may not have realized this is the most vital step in the process of beginning the company's future late-stage clinical trials next to the actual enrollment of patients. Nuvilex's success in its future trials, and quite frankly its future in general, will be pinned on its recently acquired live-cell encapsulation based treatments. According to Nuvilex's COO, Dr. Gerald Crabtree, the cloning of cells by Inno Biologics represents the crucial initial step in obtaining sufficient numbers of cells to carry out the company's late-phase clinical trials. And, if anyone understands clinical trials it's Dr. Crabtree who has spent 40 years fighting in the oncology arena and was a part of the team at Bristol Myers-Squibb that brought Taxol through clinical trials and to market. Without these cells, there will be no cell encapsulation, and as Nuvilex tries to put its live-cell encapsulation based treatments on the map, this work at Inno Biologics couldn't be any more important to the company's future. Dr. Crabtree said of the work to be done at Inno Biologics, "The fact that this step is indeed being taken illustrates Nuvilex's full and absolute commitment to doing its utmost to develop an effective and safe treatment for those suffering from this devastating and deadly disease." Nuvilex's COO explains that the process will begin with 22P1G cells being sent to Inno Biologics by Nuvilex via SG Austria. The 22P1G cells are the cells that have high activity of the enzyme CYP2B1, and this is the enzyme that activates the widely used anticancer prodrug ifosfamide into its "cancer-killing" form. Continue Reading This Article: www.stockmarketmediagroup.com/features About Stock Market Media Group Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, CEO Interviews and Feature Articles. For more information: www.stockmarketmediagroup.com Contact: Stock Market Media Group Email Contact
Disclaimer: http://alturl.com/3yt3r
When Nuvilex, Inc. (OTCQB: NVLX) announced that it had contracted Inno Biologics to generate cell clones that will be the basis of the company's future Phase III clinical trials in advanced, inoperable, pancreatic cancer, many investors may not have realized this is the most vital step in the process of beginning the company's future late-stage clinical trials next to the actual enrollment of patients. Nuvilex's success in its future trials, and quite frankly its future in general, will be pinned on its recently acquired live-cell encapsulation based treatments. According to Nuvilex's COO, Dr. Gerald Crabtree, the cloning of cells by Inno Biologics represents the crucial initial step in obtaining sufficient numbers of cells to carry out the company's late-phase clinical trials. And, if anyone understands clinical trials it's Dr. Crabtree who has spent 40 years fighting in the oncology arena and was a part of the team at Bristol Myers-Squibb that brought Taxol through clinical trials and to market. Without these cells, there will be no cell encapsulation, and as Nuvilex tries to put its live-cell encapsulation based treatments on the map, this work at Inno Biologics couldn't be any more important to the company's future. Dr. Crabtree said of the work to be done at Inno Biologics, "The fact that this step is indeed being taken illustrates Nuvilex's full and absolute commitment to doing its utmost to develop an effective and safe treatment for those suffering from this devastating and deadly disease." Nuvilex's COO explains that the process will begin with 22P1G cells being sent to Inno Biologics by Nuvilex via SG Austria. The 22P1G cells are the cells that have high activity of the enzyme CYP2B1, and this is the enzyme that activates the widely used anticancer prodrug ifosfamide into its "cancer-killing" form. Continue Reading This Article: www.stockmarketmediagroup.com/features About Stock Market Media Group Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, CEO Interviews and Feature Articles. For more information: www.stockmarketmediagroup.com Contact: Stock Market Media Group Email Contact
Disclaimer: http://alturl.com/3yt3r
